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ChelatorZinc dyshomeostasis can induce cell death. However, the mechanisms involved have not been fully elucidat-
ed in prostate cancer (PCa) cells, which differ dramatically from normal cells in their zinc handling ability.
Here, we studied the effects of the ionophore Zn-pyrithione (ZP) and the chelator N,N,N′,N′-tetrakis(2-pyri-
dylmethyl)ethylenediamine (TPEN). Both compounds induced cell death at micromolar concentrations when
incubated with androgen-dependent (LNCaP), androgen-independent (PC3, DU145) and androgen-sensitive
(C4-2) PCa cell-lines. Compared to PCa cells, RWPE1 prostate epithelial cells were less sensitive to ZP and
more sensitive to TPEN, but total cellular zinc levels were changed similarly. ZnSO4 enhanced the toxicity
of ZP, but inhibited the effects of TPEN as expected. The morphological/biochemical responses to ZP and
TPEN differed. ZP decreased ATP levels and stimulated ERK, AKT and PKC phosphorylation. DNA laddering
was observed only at low doses of ZP but all doses of TPEN. TPEN activated caspase 3/7 and induced PARP-
cleavage, DNA-fragmentation, ROS-formation and apoptotic bodies. PKC and ERK-pathway inhibitors, and an-
tioxidants protected against ZP-induced but not TPEN-induced death. Inhibitors of MPTP-opening protected
both. Cell death in response to TPEN (but not ZP) was diminished by a calpain inhibitor and largely prevented
by a caspase 3 inhibitor. Overall, the results indicated primarily a necrotic cell death for ZP and an apoptotic
cell death for TPEN. The enhanced sensitivity of PCa cells to ZP and the apparent ability of ZP and TPEN to kill
quiescent and rapidly dividing cells in a p53-independent manner suggest that ZP/TPEN might be used to de-
velop adjunct treatments for PCa.+1 508 856 5920.
.E. Carraway).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
In humans, the highest levels of Zn2+ are found in the prostate
gland, where Zn2+ appears to promote the accumulation of citrate
by inhibiting aconitase, the major enzyme involved in its metabolism
[1]. An early response in the development of prostate cancer (PCa) is
a dramatic decrease in Zn2+ levels in the malignant epithelium [2]
and a diminished ability of the cancerous cells to accumulate citrate
[3]. It has been suggested that this decrease in intracellular Zn2+
([Zn2+]i) stimulates oxidative phosphorylation by dis-inhibiting mi-
tochondrial aconitase, thus providing the malignant cells with energy
for rapid growth [4]. Supporting this notion, the growth of PCa cell
lines was inhibited by antisense knockdown of aconitase [5], as well
as by Zn2+ treatment [6]. Although Zn2+ appears to inhibit cell prolif-
eration without toxicity in some cases [7], Zn2+-treatment can also
result in apoptotic [8] or necrotic cell death [9]. Similarly, the injec-
tion of xenografted PCa tumors with zinc acetate in mice inhibited
tumor growth and extended survival times [10]. Zn2+ ionophores
have been used to enhance the uptake of Zn2+ into cells and theynot only potentiate Zn2+-toxicity in cultured PCa cell lines [11], but
also reduce the growth of xenografted PCa tumors in mice following
systemic injection [12]. These studies suggest that targeting [Zn2+]i
might be a useful therapeutic approach in PCa treatment. However,
to work toward this goal, there is a need to compare the responses
of PCa cells and normal cells to changes in Zn2+ levels, and also to
characterize the effects of Zn2+-directed agents that might be
employed to speciﬁcally alter [Zn2+]i in PCa cells without affecting
normal cells.
Considerable progress has beenmade in the development of smallmol-
ecule anticancer agents that can alter readily exchangeable [Zn2+]i in cells
[13]. Cell permeable Zn2+ chelators, such as TPEN reduce [Zn2+]i, whereas
Zn2+ ionophores such as ZP elevate [Zn2+]i. Because Zn2+ has critical roles
in cellular metabolism, growth and signaling, [Zn2+]i is tightly regulated
and any signiﬁcant changes can severely compromise cell functions [14],
inducing apoptosis [15] or necrosis [16]. Although the toxic effects of
some Zn2+-directed agents in a variety of cancer cells have been described
[17,18], few studies have involved PCa cells [11,12]. In addition, the effects
have not been compared to those in normal prostate epithelial cells, and
the mechanisms responsible for cell death have not been fully elucidated.
Much of the controversy regarding the mechanism of Zn2+-induced cell
death is attributable to the different cell systems used and the different cri-
teria employed to assess viability (e.g., LDH release, MTT reduction, ATP
545R.E. Carraway, P.R. Dobner / Biochimica et Biophysica Acta 1823 (2012) 544–557depletion, annexin V and propidium iodide staining) and to describe the
cell death process (e.g., nuclear condensation, DNA fragmentation, forma-
tionof apoptotic bodies and expressionof apoptotic proteins). For example,
someworkers have invoked an apoptoticmechanism of Zn2+-induced cell
death basedprimarily onmorphological criteria [19,8,20]. In PCa cells, Zn2+
has been shown to elicit somesigns of apoptosis (e.g., nuclear condensation
andDNAfragmentation);however, highconcentrationsof Zn2+can induce
necrosis [9].
The effects of Zn2+ ionophores and Zn2+ chelators have also not
been well investigated in PCa cells. Yu and co-workers have shown
that the Zn2+ ionophore clioquinol targets Zn2+ to lysosomes in the
PCa cell-line DU145, leading to cleavage of the proapoptotic protein
Bid [11]. Although the authors concluded that clioquinol induces an ap-
optotic death, this was based solely on the change in Bid expression. In
regards to the toxicity of Zn2+ chelators such as TPEN, aspects of the
mechanism have been studied in T lymphocytes [21], neurons [22],
breast cancer cells [23] and pancreatic cancer cells [17]; however,
there has been little work in PCa cells. TPEN has been shown to down-
regulate XIAP expression and to sensitize PC3 cells to TRAIL-induced ap-
optosis [24], but the mechanism by which TPEN causes cell death has
not been investigated in PCa cells. Thus, there is a need for further
work on the mechanisms involved in Zn2+ ionophore-induced and
Zn2+ chelator-induced cell death in PCa cells.
Maintaining the appropriate [Zn2+]i appears to be critical for cell
survival since both increased and decreased Zn2+ levels can trigger
apoptosis in a variety of cell types. Supra-physiologic Zn2+ levels
(≥50 μM ZnCl2) were found to activate the ERK pathway and induce
cell death in neuronally-differentiated PC12 cells [25] and IIC9 Chi-
nese hamster ovary embryonic ﬁbroblasts [26]. Since pre-treating
with either an ERK pathway inhibitor or a caspase inhibitor attenuat-
ed the response, the authors reasoned that Zn2+-induced cell death
occurred by an apoptotic mechanism [26]. In SH-SY5Y neuroblastoma
cells, treatment with Zn2+ plus pyrithione activated ERK and induced
the expression of PUMA (proapoptotic p53 up-regulated modulator
of apoptosis) [27]. Although an ERK pathway inhibitor blocked
these signaling steps, the effects on cell death were not investigated.
Elevated Zn2+ levels also activated ERK signaling and inhibited cell
growth in the PCa cell lines LNCaP and PC3, although this did not re-
sult in extensive cell death [7]. Similarly, treatments of neuronal cul-
tures with TPEN to reduce [Zn2+]i induced an apoptotic response that
was attenuated by a caspase inhibitor [28]. Collectively, these results
indicate that either increases or decreases in [Zn2+]i can lead to cas-
pase-mediated apoptosis that in the former case, can involve the
ERK pathway.
Evidence indicates that necrotic cell death can also involve an ac-
tive process that is mediated by extracellular signal regulated protein
kinases (ERK). In several neuronal models, caspase-independent cell
death is attenuated by ERK pathway inhibitors [29,30,31]; however,
the mechanisms by which ERK activation contributes to necrotic cell
death remain unclear. ERK can activate cytosolic phospholipase A2
(cPLA2), promoting non-apoptotic cell death most likely through
lipid peroxidation and membrane damage [32]. Activated ERK also
phosphorylates and activates the cysteine protease calpain, and cal-
pain inhibitors can attenuate necrotic death of neuronal cells [29],
as well as apoptotic death induced by doxycycline in Hela cells [33].
Whether ERK activation results in apoptotic or non-apoptotic cell
death may depend on the duration of ERK signaling as well as the spe-
ciﬁc conditions and cell type under study. The possible involvement
of ERK signaling in Zn2+-induced necrosis has not been investigated.
Here, our goals were to study the toxic effects of ZP and TPEN in
four human PCa cell lines having different growth dependencies, as
well as in immortalized (nearly normal) prostate epithelial cells. We
employed multiple criteria for cell viability and cell function, and fo-
cused attention on the early, initiating events that occur within mi-
nutes to hours of treatment. Our results show for the ﬁrst time that
PCa cells and prostate epithelial cells are differentially sensitive tothese agents, and that ZP and TPEN kill PCa cells by different mecha-
nisms. ZP rapidly and dramatically reduced the cellular ATP level, ac-
tivated ERK, protein kinase B (AKT) and protein kinase C (PKC), and
produced a strong necrotic response, although some evidence of apo-
ptosis was evident at lower doses. In contrast, TPEN treatment
resulted in caspase-3-dependent apoptosis. Zn2+ by itself (7.5–
30 μM) was not deleterious to the cells, but the effect of increasing
Zn2+ concentrations over this physiologic range was to enhance the
toxicity of ZP and to inhibit the toxicity of TPEN.
2. Materials and methods
2.1. Materials
Phospho-speciﬁc antisera to phospho-PKC (cat. #9371), phospho-
AKT (cat. #9271), phospho-ERK (cat. #9101), phospho-acetyl CoA car-
boxylase (ACC, cat. #3661) and phospho-AMP kinase (AMPK, cat.
#2531), and antibodies to AKT (cat. #9272), ERK (cat. #9102), AMPK
(cat. #2532), caspase 3 (cat. #9662) and cleaved poly-(ADP-ribose)-
polymerase (PARP, cat. #9541) were from Cell Signaling Technology
(Beverley, MA). Horse radish peroxidase (HRP)-coupled secondary
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA) or
Cell Signaling Technology, and chemiluminescent substrates were
obtained from Pierce (Rockford, IL). SB203580 and carbobenzoxy-
Asp-Glu-Val-Asp-ﬂuoromethyl-ketone (Z-DEVD-fmk) were from
Tocris Bioscience (Bristol, UK). PJ-34 was from Enzo Life Science
(Plymouth Meeting, PA). Bisindolylmaleimide I (Bis-1), Go-6976,
Go-6983, JNK-II, AG1478, U0126, U0125, PD98059, trolox, LY294002,
calpain inhibitor (ALLN) and 4′, 6-diamidino-2-phenylindole, 2HCl
(DAPI) were obtained from Calbiochem (San Diego, CA).Wortmannin,
N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), N-
acetyl-L-cysteine (NAc), pyridine N-oxide, 2-mercaptopyridine, 1-
hydroxypyridine-2-thione (pyrithione), 1-hydroxypyridine-2-thione
zinc salt (ZP), dithiothreitol (DTT), 2,3-dimercaptopropanol (DMP),
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-1H-tetraxolium bromide
(MTT), sodium orthovanadate, phenylarsine oxide, phorbol-12myris-
tate 13-acetate (PMA), 2′,7′-dichloroﬂuorescein diacetate (DCF-DA),
(+) α-tocoferol (α-Toc), butylated hydroxyltoluene (BHT), butylated
hydroxyanisole (BHA) and all other chemicals were from Sigma (St.
Louis, MO).
2.2. Tissue culture
Human PCa cell lines (PC3, DU145, C4-2, and LNCaP) were
obtained from American Type Culture Collection (ATCC; Manassas,
VA). These cells were maintained in F12K or RPMI 1640 medium sup-
plemented with 10% fetal bovine serum and penicillin/streptomycin
(100 units/ml/100 μg/ml) [34]. The immortalized normal prostate ep-
ithelial cell line (RWPE1, ATCC) was generously provided by Dr. Jack
Leonard, University of Massachusetts Medical School and was main-
tained in serum-free keratinocyte medium. Cells were passaged
every third day by washing with Dulbecco's PBS (DPBS) and treating
with trypsin-EDTA. Cells were grown in 48-well plates for viability
studies, 24-well plates for ROS studies, 6-well plates for western blot-
ting, and 10-cm dishes for Zn measurements. Cells were used at 50–
80% conﬂuence since overgrown cells showed different sensitivities.
2.3. Experimental approach
Because serum both contains and binds Zn2+, the medium was
changed to RPMI 2–20 h prior to testing. When assessing the effects
of ZnSO4 on the cellular responses to ZP or TPEN, ZnSO4 was added
from a separate solution to avoid reactions that might occur during
prior mixing. To examine the effect of elevating [Zn2+]i, ZP was
used instead of sodium pyrithione plus ZnSO4, since the kinetics of
the cellular responses to the later could potentially be confounded
546 R.E. Carraway, P.R. Dobner / Biochimica et Biophysica Acta 1823 (2012) 544–557by the time required to form the Zn(pyrithione)2 complex. Neverthe-
less, preliminary experiments indicated that ZP and sodium pyr-
ithione plus ZnSO4 behaved similarly and in accord with the
number of pyrithione moieties per mole. For example, in the cell via-
bility assay, ZP (a bidentate complex) was twice as potent as sodium
pyrithione (monodentate complex) in the presence of 3.75 μM or
7.5 μM ZnSO4 (Supplemental Results Table 1).
2.4. Assessment of cytotoxicity and cell viability
Cytotoxicity was assessed by the release of cytosolic lactate dehy-
drogenase (LDH) into the medium using the CytoTox 96 kit (Pro-
mega, Madison, WI). In brief, cells in 48-well plates were treated as
indicated, an aliquot of the medium was centrifuged to remove ﬂoat-
ing cells and 50 μl of the supernatant was reacted with the substrate
mix. The reaction was terminated after 30 min and the A492 was mea-
sured using a plate reader. The results were expressed as percent re-
lease of total cellular LDH as determined following complete cell lysis
in 0.9% Triton X-100. Cell viability was assessed by the MTT mito-
chondrial activity assay and by measuring cellular ATP levels. Follow-
ing treatments, 0.1 volume of MTT (5 mg/ml PBS) was added to the
cells, which were incubated 1–2 h depending on cell number. The
medium was aspirated, the precipitated material was solubilized in
0.5 ml DMSO by shaking for 30 min, and the A595 was measured
using a plate reader. ATP was measured by extraction of cells with
ice-cold 1.2% trichloroacetic acid (~1 ml/106 cells) following aspira-
tion of the medium. The plates were stored at−20 °C until ATP mea-
surements were performed using the Promega CellTiter-Glo
luminescent assay [34]. To assess the ability of speciﬁc agents to af-
ford protection against toxicity, a range of doses were tested based
on the literature, and the results reported were for doses that pro-
duced minimal toxicity by themselves.
2.5. Assessment of apoptosis and necrosis
To examine changes in cell and nuclear morphology, cells were
seeded into 35 mm dishes ﬁtted with collagen-coated coverslips. Fol-
lowing cell attachment overnight, the medium was replaced with
serum-free RPMI and the cells were treated with ZP, TPEN or vehicle,
and ﬁxed with methanol (−20 °C) for DAPI staining. Unﬁxed and
methanol-ﬁxed cells were photographed using a Nikon Diaphot 300
ﬂuorescence microscope equipped with a digital camera. Apoptosis
was assessed by caspase 3/7 activity, PARP cleavage, and analysis of
DNA fragmentation. The caspase-Glo 3/7 assay was performed
according to the manufacturer (Promega, Madison WI) using a mod-
iﬁed procedure. Following various treatments, cells grown in 48-well
plates were lysed in 30 mM Hepes, 0.3 mM EDTA, 0.15% CHAPS (pH
7.4) by shaking for 30 min. The caspase substrate was reacted with
the cell lysate (1:1) in a 96-well plate and luminescence was mea-
sured after 60 min. Caspase activity in treated cells was expressed rel-
ative to control cell activity. DNA fragmentation was assayed by
agarose gel electrophoresis to visualize nucleosomal DNA ladders as
described [35].
2.6. Western blotting
Western blotting was performed to assess the activation of protein
kinases (ERK, AKT, PKC and AMPK), the phosphorylation of ACC, and
the cleavage of PARP. Antibodies speciﬁc for phosphorylated and non-
phosphorylated forms of these proteins and for cleaved PARP were
used. In brief, cells were withdrawn from serum for ~16 h in RPMI,
subsequently treated with various agents, and incubated at 37 °C for
the indicated times. The medium was subsequently removed and
the cells were placed on ice for 2 min prior to scraping into ice-cold
2× SDS sample buffer containing protease and phosphatase inhibitors
(1 mM sodium vanadate, 10 mM sodium ﬂuoride, 10 mM sodiumpyrophosphate, 1 mM PMSF) and sonication for 5 s. Equal aliquots
of the samples were analyzed by SDS-PAGE and western blotting as
described by us [36].
2.7. Determination of cellular Zn2+ levels
PC3 and RWPE1 cells were grown in 10 cm dishes with either
FBS-supplemented RPMI 1640 or EGF and bovine pituitary extract-
supplemented keratinocyte serum-free medium, respectively, until
40–50% conﬂuent, at which time the medium was aspirated and
replaced with serum-free RPMI 1640. The following day the cells
were treated with either 0.24 μM ZP plus 7.5 μM ZnSO4, 4 μM TPEN,
7.5 μM ZnSO4, or DMSO vehicle for 2 h and harvested by trypsiniza-
tion (5 ml, 0.025% trypsin in DPBS, no EDTA) following aspiration
of the medium and washing with 10 ml DPBS without Mg2+ or
Ca2+. The trypsinized cells were collected in 15 ml Corex tubes on
ice, the dishes were rinsed with 5 ml DPBS, which was pooled with
the cells, and the cells were pelleted by centrifugation at 500×g for
5 min at 4 °C. After aspiration of the supernatant, the cells were
resuspended in 5.0 ml ice-cold DPBS, followed by removal of a
50 μl aliquot for protein measurement. An additional 5.0 ml of ice-
cold DPBS was added prior to centrifugation at 500×g for 5 min. Fol-
lowing a second 10 ml wash in ice-cold DPBS, the cells were centri-
fuged, the supernatant was decanted, and residual droplets were
removed from the sides of the tubes using paper towels. The cell pel-
lets were dissolved in 100 μl 67% nitric acid (Fluka) and boiled for
30 min, followed by incubation at 65 °C overnight to evaporate the
nitric acid. The residue was dissolved in 32.5 μl nitric acid, 5.0 ml deio-
nized water was added, and the samples were covered with Paraﬁlm
and stored at 4 °C. Zn2+wasmeasured by atomic absorption spectrom-
etry (AAS) using a Buck Scientiﬁc Model 210 VGP atomic absorption
ﬂame spectrometer. A Zn2+ standard curve was constructed using dilu-
tions of a commercial Zn2+ standard for AAS (Fluka).
2.8. Assay of reactive oxygen species (ROS) formation
Intracellular ROS formationwasmeasured by ﬂuorescence activated
cell sorting using DCF-DA as described [37]. In brief, PC3 cells were
grown in 24-well plates, loaded with 10 μMDCF-DA in Krebs Ringer bi-
carbonate buffer (KRB) for 30 min, treated with various agents for
30 min, and subsequently trypsinized and collected on ice for FACS
analysis. The mean ﬂuorescence intensity (10,000 cells, 485/530 nm
excitation/emission wavelengths) was determined for duplicate wells
and the data are expressed as % control (mean±SEM) obtained in 7 in-
dependent experiments.
2.9. Statistical analysis
Data were calculated as mean±SEM for 3 or more independent
experiments performed using duplicate cultures. Statistical differ-
ences were assessed using the Student's t-test for single comparisons
and ANOVA for multiple comparisons using Graph Pad Prism. Statisti-
cal signiﬁcance was deﬁned as pb0.05.
3. Results
3.1. ZP and TPEN were toxic to PC3 and other PCa cell lines
PC3 cells were treated with increasing doses of either ZP (Fig. 1A)
or TPEN (Fig. 1B), and cell viability was assessed by measuring LDH
release into the medium after various times of treatment. In general,
ZP toxicity developed more rapidly than TPEN toxicity. For example,
LDH release was evident by 12–15 h following treatment of PC3
cells with ZP (0.3–3 μM in the presence of 7.5 μM ZnSO4) and reached
near maximal levels by 24 h (Fig. 1A). The response to TPEN (1–9 μM)
was delayed in comparison, where LDH release was barely detectable
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Fig. 1. Time course and dose–response for the toxic effects of ZP (A) and TPEN (B). PC3
cells were incubated with serum-free RPMI plus the indicated concentrations of ZP,
TPEN, or DMSO (control) for the times shown. ZP was tested in the presence of
7.5 μM ZnSO4. Aliquots of the media were assayed for LDH activity, and the data is
expressed as the mean±SEM (n=3–5) percentage of LDH release compared to that
released by 0.9% triton X-100.
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Fig. 2. Time course and dose–response for the effects of ZP (A) and TPEN (B) on cell vi-
ability. PC3 cells were incubated with serum-free RPMI plus ZP, TPEN, or DMSO vehicle
(control) at the indicated concentrations. ZP was tested in the presence of 7.5 μM
ZnSO4. Viability was assessed by the MTT assay at the indicated times, and the data is
expressed as the mean±SEM (n=3–4) percent viable cells relative to the control.
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chondrial activity was also greatly diminished in a similar manner
by ZP (Fig. 2A) and TPEN (Fig. 2B), the effect of ZP being more
rapid. Both agents displayed sharp dose–response curves that gave
near maximal responses with a 3-fold increase in the threshold
doses (Fig. 3A and B). ZP and TPEN were similarly toxic to all the
PCa cell lines examined, which included androgen-dependent
(LNCaP), androgen-sensitive (C4-2) and androgen-independent
(PC3 and DU145) cells (Figs. 1–3 and data not shown). In contrast,
the immortalized normal prostate epithelial cell line (RWPE1) was
~10-fold less sensitive to ZP (Supplemental Results, Fig. 1A) and ~3-
fold more sensitive to TPEN (Supplemental Results, Fig. 1B). These
ﬁndings suggested that the elevations in cellular Zn2+ were more
toxic to PCa cells than to normal cells, whereas the opposite was
true for decreases in cellular Zn2+. One possibility is that PCa cells
are unable to sequester internal Zn2+ in the same manner as normal
prostate epithelial cells (see Discussion).
3.2. The addition of Zn2+ has opposite effects on the toxicity of ZP and
TPEN in PC3 cells
The addition of ZnSO4 to the culture medium shifted the dose–
response curve for ZP toxicity to the left in PC3 cells, indicating
that Zn2+ enhanced the toxicity of ZP (Fig. 3A). For example,
Zn2+ at concentrations found in human blood (15 μM) increased
the potency of ZP by ~8-fold, but was by itself non-toxic
(Table 1). These results suggest that ZP acts as an ionophore to in-
crease [Zn2+]i to toxic levels, consistent with its moderate Zn2+ af-
ﬁnity (Ka~106 M) and previous results indicating that it acts as aZn2+ ionophore [22]. This idea is also supported by the observation
that pyrithione was non-toxic in the absence of Zn2+ (Table 1). Fur-
thermore, 2-mercaptopyridine and pyridine N-oxide (analogs of
pyrithione that are not Zn2+ ionophores) were not toxic, even at
higher doses and in the presence of added ZnSO4 (Table 1).
In contrast, ZnSO4 shifted the dose–response curve for TPEN toxic-
ity to the right in PC3 cells (Fig. 3B), with 15 μM Zn2+ decreasing the
potency by ~8-fold (Table 1). Since TPEN binds Zn2+ nearly irrevers-
ibly (Ka~1015 M), [22], the most likely explanation is that TPEN toxic-
ity results from a reduction in [Zn2+]i and that this is prevented by
the addition of Zn2+ to the medium occupying the TPEN binding
site. This idea is also supported by the observation that Ca-EDTA, a
cell-impermeable Zn2+ chelator, was non-toxic (Table 1).
3.3. ZP increases Zn2+ levels in PC3 and RWPE1 cells
Cellular Zn2+ levels were determined by AAS to examine whether
differences in Zn2+ concentrations might account for the differential
sensitivity of PC3 and RWPE1 cells to ZP and TPEN. For these experi-
ments, cells were grown to approximately half conﬂuency and
growth medium was exchanged for serum-free RPMI 1640 the day
prior to the experiment. Basal mean Zn2+ levels in PC3 and RWPE1
cells were 0.29±0.05 and 0.23±0.03 μg/mg protein, respectively
(Fig. 4). The value for PC3 cells is similar to previous reports
[38,39]; however, RWPE1 cells have previously been reported to
have higher basal Zn2+ levels [38], and this difference is most likely
due to the different media employed (see Discussion). 2-way
ANOVA indicated that there were signiﬁcant treatment (pb0.0001)
and cell line (pb0.0057) effects and post-hoc pairwise comparisons
revealed that the treatment effect was due to signiﬁcant ~3-fold
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Fig. 3. Treatment of cells with ZnSO4 shifted the dose–response for the toxic effect of ZP
to the left (A) whereas it shifted that for TPEN to the right (B). In A, PC3 cells were in-
cubated in serum-free RPMI with ZP plus the indicated concentrations of ZnSO4 or
DMSO vehicle (control) for 18 h. In B, cells were incubated with TPEN plus the indicat-
ed concentrations of ZnSO4 or DMSO for 30 h. Viability was assessed using the MTT
assay and the results are expressed as the mean±SEM (n=4–5) percentage reduction
in MTT activity relative to control.
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0.24 μMZP plus 7.5 μMZnSO4 in both cell lines (pb0.001 as compared
to control cells in both cases). Zn2+ levels were signiﬁcantly lower inTable 1
Effect of ZnSO4 on the ability of ZP, TPEN and related agents to induce toxicity.
Agent ZnSO4 (μM) IC50 (μM)a
None 15 Not toxic
30 Not toxic
ZP 0 1.7±0.1
5 0.50±0.1⁎⁎
15 0.20±0.03⁎⁎
TPEN 0 2.1±0.4
5 7.3±0.3⁎⁎
15 16.5±0.7⁎⁎
Sodium pyrithione 0 N100
15 0.17±0.02⁎⁎
2-Mercaptopyridine 0 N100
15 N100
Pyridine N-oxide 0 N100
15 N100
Ca-EDTA 0 N200
a The agents were incubated with PC3 cells in the presence of the indicated concen-
trations of ZnSO4 for 28 h (TPEN) or 16 h (all others). MTT was then added for an ad-
ditional 2 h to assess mitochondrial activity. IC50 was deﬁned as the concentration of
the agent that decreased mitochondrial activity by 50%. Results (mean±SEM) are
from at least 3 independent experiments.
⁎⁎ The value obtained was signiﬁcantly different from that in the absence of ZnSO4
(pb0.01).RWPE1 as compared to PC3 cells following ZP plus Zn2+ treatment
(0.58±0.09 vs 0.81±0.07 μg/mg protein, pb0.01). There were no
signiﬁcant differences between the other treatment groups, although
the mean Zn2+ levels in cells treated with 4 μM TPEN for 2 h were
somewhat lower than in control cells (~72 and 87% of control for
PC3 and RWPE1 cells, respectively, Fig. 4). These observations suggest
that the increase in cellular Zn2+ levels following ZP plus ZnSO4 treat-
ment is somewhat muted in RWPE1 cells, and this could potentially
render these cells more resistant to the toxic effects of ZP plus
ZnSO4 treatment.
3.4. TPEN triggers apoptosis, but ZP results in oncotic/necrotic cell death
PC3 cells treated with 2–20 μM TPEN exhibited classic signs of ap-
optosis, including budding, chromatin condensation, and nuclear and
DNA fragmentation [40]. TPEN treatment resulted in the appearance
of clustered buds that resembled grape bunches, indicative of apopto-
sis (Fig. 5C and D), and DAPI staining of methanol-ﬁxed PC3 cells
revealed clear nuclear fragmentation and chromatin condensation in-
cluding crescent-shaped chromatin deposits by 4 h following TPEN
treatment (Supplemental Results Fig. 2). TPEN treatment of both
PC3 and DU145 cells also resulted in DNA fragmentation at 6 h (Sup-
plemental Results, Fig. 3), which was evident as early as 3 h and con-
tinued to increase in intensity during the next 12 h (results not
shown). In contrast, ZP treatment resulted in the appearance of cyto-
plasmic blebs that appeared to coalesce over time (Fig. 5A and B),
reminiscent of the early stages of oncotic/necrotic cell death [41].
Treatment of PC3 cells with a lower dose of ZP (0.2 μM) resulted in
DNA fragmentation; however, higher doses appeared to suppress
this effect (Supplemental Results Fig. 3). There was also little evi-
dence of nuclear fragmentation and chromatin condensation in
DAPI-stained PC3 cells treated with 0.4 μM ZP plus 7.5–15 μM Zn2+
for 4 h, again consistent with oncosis/necrosis rather than apoptotic
cell death. In keeping with this hypothesis, ZP treatment also caused
a precipitous decline in cellular ATP levels (see Section 3.6).
3.5. TPEN, but not ZP, activated caspase 3/7 and induced PARP cleavage
Apoptosis generally requires the activation of the caspase family
of proteases, although caspase-independent apoptosis can occur
[42]. Exposure of PC3 cells to TPEN activated caspase 3/7 over the
same critical dose range that induced cell death (Fig. 6A). Caspase
3/7 activity was signiﬁcantly elevated above control by 4 h and it con-
tinued to rise to reach a peak at 15–20 h. In contrast, ZP did not en-
hance caspase 3/7 activity at any of the doses tested from 0.1 to
10 μM in the presence or absence of 7.5–15 μM ZnSO4 (Fig. 6A). Sim-
ilar results were obtained with DU145 and LNCaP cells (results not
shown).
Poly (ADP ribose) polymerase-1 (PARP), an enzyme involved in
DNA repair, is a major cleavage target for caspase 3 and a marker
for cells undergoing apoptosis. Treatment of PC3 cells and RWPE1
cells with TPEN (≥1 μM) dose-dependently induced PARP cleavage
(Fig. 6B and C), and this response was prevented by the addition of
ZnSO4 (Fig. 6D). In contrast, ZP (0.2–1.0 μM) in the presence of
7.5 μM ZnSO4 or ZP alone (0.2–10 μM) did not induce PARP cleav-
age (Fig. 6B and C). In addition, pretreatment of PC3 cells with
the caspase inhibitor Z-DEVD-fmk largely prevented the effect of
TPEN on cell viability (Table 2), but afforded little protection
against ZP (Table 3). Similar results were obtained using DU145
and LNCaP cells (results not shown). Apoptosis is an active process
that requires protein synthesis [43]. Consistent with an apoptotic
mechanism, pretreatment with cycloheximide diminished the
toxic effect of TPEN (Table 2). In contrast, cycloheximide did not
inhibit the response to ZP (Table 3). Taken together with the re-
sults in Section 3.3, these ﬁndings suggest that TPEN diminished
cell viability by inducing an apoptotic response involving caspase
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Fig. 4. Zn2+ levels increased signiﬁcantly following treatment with ZP plus ZnSO4. PC3 (A) and RWPE1 (B) cells grown to ~50% conﬂuence were equilibrated in serum-free RPMI
1640 for 1 day, at which time they were treated with 7.5 μMZnSO4 plus DMSO vehicle, 4 μMTPEN, 7.5 μM ZnSO4 plus 0.24 μMZP, or DMSO vehicle (0.1% ﬁnal concentration) for 2 h.
The cells were harvested and processed for determination of Zn2+ levels by AAS as described in Materials and methods. * indicates that the results were signiﬁcantly different
(pb0.001) from the corresponding control and each of the other treatment groups.
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mechanism.
DNA damage can lead to apoptotic cell death mediated by activa-
tion of the p53 pathway [42]. However, the fact that pretreatment of
LNCaP cells (p53+) or PC3 cells (p53−) with the p53 inhibitor piﬁ-
thrin did not protect against the toxicity of TPEN (Table 2) or ZP
(Table 3) argues against the involvement of p53 in either mechanism
of cell death.PC3, Control, 2 hr
DU145, Control, 4 hr
A
C
Fig. 5. Changes in cell morphology following ZP or TPEN treatment. PC3 or DU145 cells were
the medium was replaced with serum-free RPMI 1640. PC3 cells were treated with either (
DU145 cells were treated with either (C) ethanol vehicle (Control), or (D) 4 μM TPEN. Cells
micrographs are shown for the earliest treatment times where there were clear morpholog
dicative of oncosis/necrosis (B) or budding, indicative of apoptosis (D). TPEN and ZP plus Z3.6. ZP decreased cellular ATP levels, causing the phosphorylation of
AMPK and ACC
The fact that ZP treatment induced morphological changes that re-
sembled those described for oncotic/necrotic cell death prompted us
to examine possible changes in cellular metabolism by measuring
the effects of ZP on cellular ATP levels in PC3 and DU145 cells. For ex-
ample, 10 μM ZP plus 15 μM ZnSO4 treatment resulted in a rapid andB
D
PC3, 0.4 μM ZP, 2 hr 
DU145, 4 μM TPEN, 4 hr 
grown in Ham's F12-K medium containing 10% FBS and on the day of the experiment,
A) DMSO vehicle plus 7.5 μM ZnSO4 (Control), or (B) 0.4 μM ZP plus 7.5 μM ZnSO4, and
were photographed at 2, 4 and 9 h after treatment (400× original magniﬁcation) and
ical changes (2 h for ZP plus Zn2+ and 4 h for TPEN). Arrows indicate either blebs, in-
nSO4 produced similar results when the cell lines were reversed.
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Fig. 6. TPEN produced signs of apoptosis that were not evident with ZP, including activa-
tion of caspase 3/7 (A) and cleavage of PARP (B and C). In A, PC3 cells were treated with
the indicated concentrations of either TPEN, or ZP plus 7.5 μM ZnSO4. After the times
shown, caspase 3/7 was measured in cell extracts, and the data (mean±SEM) are
expressed relative to the starting activity (0 h). The results are representative of 3 indepen-
dent experiments. ZP was also tested at 0.1 μM, 0.3 μM, 3 μM and 10 μM in the presence
and absence of 15 μMZnSO4with similar results (not shown). In B, RWPE1 cells were trea-
tedwith DMSOvehicle (Con), or the indicated concentrations of ZP or ZP plus 15 μMZnSO4
or TPEN for 17 h. Cell lysateswere subjected towesternblottingusing speciﬁc antibodies to
cleaved PARP and ERK (loading control). In C, PC3 cells were treated as described in B for
21 h, and cell lysates were analyzed. In D, PC3 cells were treated with DMSO vehicle
(CON), 10 μMTPEN, 10 μMTPEN plus 15 μMZnSO4, or 15 μMZnSO4 alone for the indicated
times. Cell lysates were analyzed by western blotting using antibodies speciﬁc to cleaved
PARP and β-actin (loading control).
Table 2
Protective effects of various agents on the toxicity response to TPEN.
Substance Concentration
(μM)
Cell death at 18–24 h
(% Protection)
Z-DEVD-fmka 100 72±6⁎⁎
Cycloheximide 330 12±4⁎
3300 25±8⁎
Piﬁthrinb 20 11±6
CsA 0.33 24±5⁎⁎
1 49±5⁎⁎
FK506c 0.33 26±7⁎
1 52±11⁎⁎
Calpain inhibitor 7 19±4⁎
14 21±5⁎
AACOF3 1 5±2
2.5 11±5
Trolox 60 0
NAc 3000 0
9000 0
PC3 cells were pretreated with the indicated agents for 60 min prior to addition of 2 μM
TPEN. After incubation for ~24 h, LDH release was measured to assess cell viability and
the % protection against TPEN-induced cell death was calculated as indicated in Table 3.
The results (mean±SEM) are for at least 3 experiments.
a Added 5 min before TPEN.
⁎⁎ Results were signiﬁcantly different from 0% protection (pb0.01).
⁎ Results were signiﬁcantly different from 0% protection (pb0.05).
b Piﬁthrin also did not protect against TPEN when tested in LNCaP cells at doses from
10 to 40 μM (% protection, 2±2, n=3 experiments).
c FK506 also gave similar protection against TPEN when tested in LNCaP cells at the
same doses.
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30 min, ~60% after 1 h and ~98% after 15 h (Fig. 7A). The fall in ATP
levels paralleled the decline in viability (assessed by the MTT
assay), and both of these effects preceded cellular LDH release by sev-
eral hours (Fig. 7B). ATP levels fell by N90% within 12 h at all ZP doses
that induced cell death at 24 h. The half lives for the decline in ATP
levels and viability were inversely related to the ZP dose (Table 4).
At the threshold dose (0.125 μM ZP plus 7.5 μM ZnSO4), the half
lives were ~3.5 h (ATP) and ~4.1 h (MTT), which was N8 h before sig-
niﬁcant LDH release occurred (Fig. 1). When PC3 cells were treatedfor 12 h with a constant dose of ZP (0.25 μM) in the presence of in-
creasing concentrations of ZnSO4 (3.75 μM to 30 μM), cellular ATP
levels fell progressively from ~70% control to ~3% control (results
not shown). These results show that treatments with ZP plus ZnSO4
caused ATP levels to fall in a dose- and time-dependent manner,
and at all doses tested, the fall in ATP occurred well before cell
death. The decrease in ATP levels was likely due to an inhibition of
cellular metabolism and was consistent with an oncotic/necrotic
death mechanism. In contrast, 10 μM TPEN did not decrease ATP
levels until ~8 h of exposure, and even after 20 h, ATP levels were
~40% of control values (Fig. 7A). The decline in ATP following TPEN
treatment correlated temporally with LDH release (Fig. 1B), suggest-
ing that the fall in ATP, in this case, was secondary to cell death.
In keeping with the above results, ZP (but not TPEN) activated the
metabolic sensor AMPK, which is sensitive to increases in the AMP/ATP
ratio [44], resulting in the phosphorylation of AMPK and its downstream
target, ACC (Fig. 8A–C). These effects were Zn2+-dependent (Fig. 8A) and
fell off at higher doses of ZP (Fig. 8B), perhaps due to the reduced ATP
levels, whichmay have become limiting for the kinases involved, or a dif-
ference in time course. The ZP-inducedmetabolic insult could be delayed
by providing the cells with additional pyruvate or citrate, which dimin-
ished the early fall in ATP levels (Table 3) and inhibited the phosphoryla-
tion of AMPK and ACC (Fig. 8C). Although pyruvate and citrate delayed
the metabolic insult, this did not prevent the ZP-induced LDH release at
20 h (Table 3), indicating that cell death was not solely due to the early
fall in ATP levels.
3.7. Phosphorylation of ERK, AKT and PKC occurred following ZP, but not
TPEN, treatment
To identify intracellular signaling pathways that might be in-
volved in the different responses to ZP and TPEN, we monitored acti-
vation of ERK, AKT and PKC by western blotting of cell extracts using
phospho-speciﬁc antibodies. ZP, but not TPEN, treatment of PC3 cells
resulted in the rapid (within 10 min) and prolonged (N6 h) activation
of ERK (Fig. 8D), and increased the phosphorylation of AKT and PKC
(Fig. 8B and Supplemental Results Figs. 4 and 5). These responses, es-
pecially ERK phosphorylation, were Zn2+-dependent (Fig. 8A) and
Table 3
Protective effects of various agents on the toxic responses to ZP.
Agent Concentration
(μM)
ATP at 2 ha
(% Protection)
Cell death at 15–20 hb
(% Protection)
Z-DEVD-fmkc 100 6±2 0
Cycloheximide 330 Nd 7±6
3300 Nd 4±3
Piﬁthrin 20 Nd 11±4
Pyruvated 5000 72±6⁎⁎ 0e
Citrated 5000 75±9⁎⁎ 0e
U0126 10 4±2 76±5⁎⁎
Bis-1 3 0 69±5⁎⁎
Go-6976 3 0 65±8⁎⁎
Go-6983 3 0 72±5⁎⁎
Wortmannin 4 1±1 2±1
LY294002 40 0 0
AG1478 10 2±2 3±2
SB203580 40 6±6 0
JNK-II 20 0 2±1
CsA 0.33 Nd 27±5⁎
1 Nd 39±4⁎
FK506f 0.33 Nd 28±7⁎
1 Nd 38±8⁎
Calpain inhibitor 7 Nd 4±2
14 Nd 7±4
AACOF3 1 Nd 2±2
2.5 Nd 4±3
NAc 9000 99±2⁎⁎ 99±2⁎⁎
DTT 5000 92±3⁎⁎ 100±3⁎⁎
DMP 500 94±3⁎⁎ 98±2⁎⁎
α-Tocoferol 130 5±3 44±7⁎⁎
Trolox 60 1±1 69±4⁎⁎
Ascorbic acid 1000 0 8±2
Apigenin 5–30 0 0
BHA 5–20 0 0
BHT 5–20 0 0
PC3 cells were pretreatedwith the indicated agents or corresponding vehicle (control) for
60 min prior to assessing the toxic effects of ZP plus ZnSO4 as described below. In initial
studies not reported, each agent was tested over a 10-fold range in concentration to
select the optimal dose or doses used here. The protection afforded by the agents was
measured and the results (mean±SEM) represent at least 3 independent experiments.
Nd, not determined.
a In one set of experiments, cells were preincubated and subsequently treated with
4 μM ZP plus 15 μM ZnSO4 for 2 h, cellular ATP was measured, and % protection against
the effect of ZP was calculated from the % decrease in ATP in cells preincubated with
agent relative to the corresponding vehicle control. The formula was: % protection=
[% decrease (control)−% decrease (agent)]/% decrease (control)×100.
b In a second set of experiments, cells were preincubated and subsequently treated
with 0.24 μM ZP plus 7.5 μM ZnSO4 for 14–20 h. LDH release into the medium was
measured and % protection against the effect of ZP was calculated from the % release
(above basal) relative to the vehicle control. The formula was: % protection=[% release
(control)−% release (agent)]/% release (control)×100.
c Z-DEVD-fmk was added 10 min before exposure to ZP.
d The fall in ATP levels was delayed by adding pyruvate or citrate but it still occurred.
⁎⁎ Results were signiﬁcantly different from 0% protection (pb0.01).
e Protection was determined by measuring cellular ATP due to interference in the
LDH release assay.
⁎ Results were signiﬁcantly different from 0% protection (pb0.05).
f FK506 also gave similar protection against ZP when tested in LNCaP cells at the
same doses.
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Fig. 7. ZP treatment decreased cellular ATP levels more rapidly than TPEN (A) and this
decrease preceded LDH release (B). (A) PC3 cells in serum-free RPMI were treated with
either 10 μM ZP plus 15 μM ZnSO4, or 10 μM TPEN for the indicated times. Cellular ATP
levels were determined and the data are expressed as the mean±SEM (n=3) relative
to time zero. (B) PC3 cells were treated with 8 μM ZP plus 15 μM ZnSO4 for the indicat-
ed times. Cellular ATP levels and mitochondrial function (MTT assay) were assessed
using cell lysates and LDH release into the medium was measured and the data are
expressed as the mean±SEM (n=3) percent maximal response.
Table 4
Half lives for ZP-induced decrease in cellular ATP and viability (MTT).
ZP (μM) ATP half lifea
(h)
MTT half lifea
(h)
0.06 N6 N6
0.125 3.53±0.38 4.14±0.25
0.25 2.00±0.25 2.38±0.08
1.0 1.16±0.17 1.44±0.13
4.0 0.97±0.24 1.13±0.18
PC3 cells in 48-well plates were incubated with the indicated concentrations of ZP plus
7.5 μM ZnSO4 for 1.25, 2.5, 3.5 and 6 h. For each experiment, matched plates were used
to measure cellular ATP and mitochondrial activity (MTT) at each time point. Half lives
were calculated from plots of the data. Results (mean±SEM) are from 4 independent
experiments. Note that cellular ATP levels fell more rapidly than MTT activity at each
dose of ZP, although the half lives were not statistically different at a given dose.
Comparison with the results in Fig. 1A shows that the decrease in cellular ATP and
mitochondrial activity occurs many hours prior to cell death as indicated by LDH release
into the medium, even for the threshold dose of 0.125 μM ZP. For both ATP and MTT,
there was a statistically signiﬁcant (pb0.05) decrease in the half life as the dose of ZP
increased from 0.06 to 0.125 μM, from 0.125 to 0.25 μM, and from 0.25 to 1.0 μM.
a Half life was deﬁned as the time at which the activity was decreased by 50%.
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(Fig. 8C). However, at extremely high doses of ZP (Fig. 8B) or in the
presence of supra-physiologic levels of Zn2+ (Fig. 8A), these re-
sponses to ZP were sometimes diminished, perhaps due to the re-
duced ATP levels or a difference in time course. In contrast to AMPK
and ACC, the phosphorylation of ERK in response to ZP was not due
to the metabolic insult since addition of pyruvate or citrate did not
block the response (Fig. 8C). The increases in phospho-ERK and phos-
pho-AKT were selectively inhibited by MEK (U0126 and PD98059)
and PI3K (wortmannin) inhibitors, respectively (Fig. 8C and Supple-
mental Results Figs. 4 and 5). These results suggest that activation
of the ERK, AKT and PKC pathways could be mechanistically involved
in ZP toxicity. One possible mechanism by which Zn2+ might activateERK and AKT involves the inhibition of tyrosine phosphatases [45].
Supporting this idea, we found that the tyrosine phosphatase inhibi-
tors, peroxovanadate (20 μM) and phenylarsine oxide (10 μM), acti-
vated ERK similarly to ZP (results not shown).
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western blots were probed with P-ERK and β-actin antibodies as indicated. The results shown are representative of at least 3 similar experiments.
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toxicity
To determine whether ZP activation of either ERK, AKT, or PKC
was required for cell toxicity, PC3 cells were pretreated with speciﬁc
inhibitors, subsequently treated with ZP, and cellular ATP levels and
cell death were measured at 2 h and 15–20 h, respectively. Pretreat-
ment with the MEK inhibitor (U0126) and various PKC inhibitors
(Bis-1, Go-6983, Go-6976) protected against the toxic response as
measured by LDH release, but had little impact on the rapid decline
in ATP in ZP-treated PC3 cells (Table 3). Protection by these agents
was dose dependent (Fig. 9), and occurred at doses known to be se-
lective for the putative target [46]. In contrast, PI3K inhibitors that
blocked AKT activation (wortmannin, LY294002) had no protective
effect on either cellular ATP levels or cell viability following ZP treat-
ment (Table 3). Several other kinase inhibitors were similarly ineffec-
tive, including the EGF receptor tyrosine kinase inhibitor (AG1478),
the p38 MAPK inhibitor (SB203580), and the JNK inhibitor (JNK-II)
(Table 3). These results suggest that ZP-induced cell death requires
activation of both the ERK and PKC pathways, but the decline in ATP
levels is not absolutely essential.
3.9. The toxic effects of ZP and TPEN involve opening of the mitochondrial
permeability transition pore (MPTP)
Because opening of the MPTP can participate in cell death mecha-
nisms, we analyzed the effects of cyclosporine A (CsA) and FK506,
two well-characterized inhibitors of MPTP opening. Pretreatment of
PC3 cells and LNCaP cells for 1 h with either CsA or FK506 protected
against the toxic effects of ZP and TPEN. LDH release in response toZP was inhibited by as much as 39% (Table 3) while the response to
TPEN was inhibited by as much as 52% (Table 2), suggesting that
MPTP opening was involved in the toxicity of both ZP and TPEN.
Opening of the MPTP is sometimes associated with changes in Ca2+
levels and the activation of calpain I, which can activate the caspase
family and release apoptosis-inducing factor (AIF) from mitochon-
dria, promoting DNA fragmentation and cell death [47]. In some sys-
tems, ERK activation can lead to a cPLA2-dependent cell death
involving oxidative impairment of mitochondrial function [32].
Here, we found that the calpain I inhibitor diminished TPEN-induced
toxicity (Table 2) without inhibiting the response to ZP (Table 3),
suggesting that calpain I participates in the toxic effect of TPEN and
that the ensuing apoptosis could involve AIF release. On the other
hand, no signiﬁcant cytoprotection was afforded by AACOF3 (Tables 2
and 3), indicating that cPLA2 was not a major contributor to either ZP
or TPEN-induced cell death.
3.10. Pretreatment with some antioxidants protected against ZP, but not
TPEN toxicity
Intracellular Zn2+ overload can enhance the generation of ROS in
some cells [48], and pretreatment with antioxidants, has been
shown to protect against oxidative damage [49]. Therefore, we exam-
ined the ability of antioxidants, including ascorbic acid (vitamin C),
apigenin (ﬂavonoid), α-tocoferol (vitamin E), trolox (vitamin E ana-
log), BHA, BHT and N-acetyl-L-cysteine (NAc) to mitigate ZP toxicity
in PC3 cells. NAc diminished both the decrease in cellular ATP levels
and cell death following ZP treatment, and similar results were
obtained with other sulfhydryl-agents such as DTT and DMP
(Table 3). Trolox and α-tocoferol also attenuated cell death in a
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tect against the fall in cellular ATP levels (Table 3). In contrast, ascor-
bic acid, apigenin, BHA and BHT had no protective effects (Table 3).
These results indicate that ROS is involved in ZP-induced cell death
but ROS formation is not required for the reduction in ATP. Although
antioxidant sulfhydryl agents (e.g., NAc and DTT) inhibited both the
fall in ATP levels and the ensuing cell death (Table 3), this is most
likely attributable to their ability to react with Zn2+ and limit its
availability to pyrithione [50]. In contrast to the results for ZP, the
toxic effect of TPEN was not inhibited by trolox and NAc (Table 2),
suggesting that oxidative ROS were not essential to the mechanism.
3.11. The antioxidants NAc and trolox protect cells from ZP toxicity
through different mechanisms
NAc shifted the dose–response curve for the toxic effect of ZP to
the right in a parallel manner (Fig. 10A), reducing potency without al-
tering efﬁcacy (Table 5). In this regard, NAc was similar to calf serum
(Table 5), which is known to contain Zn2+-binding proteins. In con-
trast, trolox, Go-6983 and U0126 ﬂattened the dose–response curve
for the toxic effect of ZP (Fig. 10B and C), reducing efﬁcacy but having
much less effect on potency (Table 5). Thus, unlike NAc, the protec-
tive effects of trolox, Go-6983 and U0126 could not be overcome by
providing additional ZP or Zn2+ in the range of 7.5–30 μM (Fig. 10
and Supplemental Results Fig. 6). These ﬁndings indicate that trolox,
Go-6983 and U0126 disrupt key cellular process(es) required for ZP
toxicity, whereas NAc appears to compete with ZP for Zn2+, most
likely reducing Zn2+ entry into the cells.
3.12. ZP but not TPEN increased cellular levels of ROS
In keeping with the protective effects of antioxidants, ZP signiﬁ-
cantly increased ROS levels in PC3 cells by 20–40% within 30 min
(Fig. 11A). Consistent with the dose-dependence for the decrease in
PC3 cell viability (Fig. 3A), ZP was effective at 0.24 μM, 0.8 μM and
2.4 μM in the presence of 7.5 μM Zn2+ and at 8 μM and 24 μM in the
absence of added Zn2+. As expected, pre-treating the cells with
60 μM trolox abolished the response to each of the ZP doses tested
(Fig. 11B–F). The effect of ZP was also inhibited by 10 μM U0126, al-
though the results were signiﬁcant only at the 0.8 μM and 2.4 μM
doses of ZP (Fig. 11C and D, respectively). In contrast, 3 μM Bis-1
did not diminish the response to ZP at any dose tested (Fig. 11B–F),
although 3 μM Bis-1 blocked the effect of PKC activator PMA (1 μM)[agent], μM
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cells were pretreated with the agents shown at the doses indicated for 1 h prior to chal-
lenge with 0.24 μM ZP plus 7.5 μM ZnSO4. After 15–20 h, LDH was measured in the me-
dium and % protection was calculated as in Table 3. The results (mean±SEM)
represent 4–8 independent experiments, half involving each cell-line. Note that
U0126, which can inhibit MEK with ~10-fold higher potency than U0125, was more ef-
fective here. Also, trolox is more potent than α-tocoferol as an antioxidant.on ROS levels (results not shown). These results indicate that ZP (at
doses that induce cell death) stimulates ROS formation by a mecha-
nism involving the ERK pathway.
3.13. The cytoprotective effects of trolox, Go 6983 and U0126 were non-
additive
Results obtained using a variety of cells and other stimuli have
shown that ROS formation is connected to the activation of PKC and
the ERK pathway, suggesting that the cytoprotective effects of trolox,[ZP], μM
7.5 μM ZnSO4
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Fig. 10. NAc shifted the dose–response curve for the toxic effect of ZP to the right, re-
ducing potency (A), whereas trolox, Go-6983 and U0126 ﬂattened the dose–response
curve, reducing efﬁcacy (B and C). PC3 cells were pretreated with the agents (NAc, tro-
lox, Go-6983, U0126 or vehicle) at the concentrations indicated for 1 h prior to chal-
lenge with ZP at the concentrations indicated plus 7.5 μM ZnSO4. After 14 h, LDH
release into the medium was measured as in Fig. 1. The results (mean±SEM) repre-
sent 3–4 independent experiments. Note that similar results were obtained at 30 μM
ZnSO4 (Supplemental Results Fig. 6), indicating that the protective effects of trolox,
Go-6983 and U0126 could not be overcome by providing additional Zn2+.
Table 5
Effect of various agents on potency and efﬁcacy of ZP in the toxicity assay.
Agent
(concentration)
Relative potencya
(% Control)
Relative efﬁcacyb
(% Control)
Control (vehicle) 100 100
U0126 (10 μM) 111±7 28±2⁎⁎
Trolox (60 μM) 81±9 38±16⁎
Go-6983 (3 μM) 104±5 60±8⁎⁎
NAc (150 μM) 31±2⁎⁎ 96±2
Calf serum (1%) 56±2⁎⁎ 97±3
Calf serum (3%) 40±4⁎⁎ 97±3
PC3 cells were pretreated with the indicated agents or the appropriate control for
60 min prior to incubation with various doses of ZP (0.06–1.8 μM) plus 7.5 μM ZnSO4
for 15–20 h. LDH release into the medium was measured and the log dose–response
relationship was plotted. EC50 was deﬁned as the [ZP] that increased LDH release by
50% of the maximum for each agent. The efﬁcacy was deﬁned as the maximal effect
in the presence of each agent relative to control. The results (mean±SEM) represent
at least 3 experiments.
a Relative potency was calculated by the formula: 100%×EC50 (control)/EC50
(agent).
b Relative efﬁcacy was calculated by the formula: 100%×efﬁcacy (agent)/efﬁcacy
(control).
⁎⁎ Results were signiﬁcantly different from the control (pb0.01).
⁎ Results were signiﬁcantly different from the control (pb0.05).
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same pathway. Consistent with this idea, when PC3 cells were treated
with pair-wise combinations or all three of these inhibitors at doses
that individually produced ≅60% protection, there was no additional
protection (Supplemental Results Table 2). However, neither trolox
nor Bis-1 diminished ERK phosphorylation in response to ZP (Supple-
mental Results Fig. 7), indicating that neither PKC activation nor ROS
are required for ERK activation in ZP-treated cells. These results to-
gether with the results discussed in Section 3.12 indicate that the
ERK pathway is upstream of ROS formation and PKC activation in
the ZP-induced death pathway. Thus, if the protective effects of
these inhibitors are due to actions on a common pathway, trolox
and Go-6983 must be exerting their effects downstream of ERK
activation.
4. Discussion
The striking new ﬁndings reported here show that 1) four PCa cell
lines with different growth dependencies were similarly sensitive to
the toxic effects of ZP and TPEN; 2) as compared to PCa cells, immor-
talized prostate epithelial cells were ~10-times less sensitive to ZP
and ~3-times more sensitive to TPEN; 3) ZP caused a comparable
fold increase in total cellular Zn2+ levels in PC3 and RWPE1 cells; 4)
ZP killed PCa cells primarily by a necrotic mechanism that involved
a rapid fall in ATP levels, an activation of ERK and PKC, and a genera-
tion of ROS; 5) ERK activation was upstream of ROS generation and
PKC activation in the ZP-induced death pathway; 6) the fall in ATP
levels did not require ERK activation or ROS formation; 7) TPEN killed
PCa cells by an apoptotic mechanism that involved opening of the
MPTP and activation of caspase 3, and was suppressed by inhibitors
of calpain I and caspase 3; and 8) although the effects of ZP and
TPEN were not inhibited by general antioxidants, vitamin E-related
compounds protected against ZP-induced toxicity. Perturbations in
readily exchangeable [Zn2+]i can have devastating consequences on
cells [14], and our ﬁndings demonstrate that the primary mechanism
of cell death induced by elevated [Zn2+]i is necrosis, whereas that for
reduced [Zn2+]i is apoptosis.
TPEN toxicity in these cells most likely resulted from the chelation
of [Zn2+]i and the consequent activation of caspase-3 to trigger apo-
ptosis. Our observations that TPEN toxicity could be reversed by the
addition of equimolar amounts of Zn2+ and that the cell impermeable
chelator, Ca2+-EDTA, was not toxic indicate that chelation of [Zn2+]i
underlies TPEN-induced toxicity, consistent with previous work inother cells [51,21,23,17]. However, chelation of Zn2+ would not nec-
essarily reduce the total Zn2+ levels in cells, which is consistent with
our measurements by AAS showing that treatment with 4 μM TPEN
for 2 h led to a non-signiﬁcant reduction to 72% and 87% control in
PC3 and RWPE1 cells, respectively (Fig. 4). Since TPEN produced the
classic signs of apoptosis, activated caspase-3/7 and induced PARP
cleavage in PCa cells, it is likely that most of the cell death was attrib-
utable to the apoptotic response. This interpretation is supported by
our ﬁnding that the caspase-3 inhibitor, Z-DEVD-fmk, protected
against TPEN toxicity. Zn2+ inhibits caspase-3, and relief of this inhi-
bition by Zn2+ depletion results in caspase-3 activation [52], suggest-
ing that TPEN may activate caspase-3 through this mechanism. Since
TPEN can downregulate the expression of XIAP, a protein that sup-
presses cell death by inhibiting caspase activity, this might also con-
tribute to the activation of caspase-3 [24]. In some cells, Zn2+
depletion induces mitochondrial stress, which leads to opening of
the MPTP and cytochrome c-mediated caspase activation [21]. That
this pathway also contributes to caspase-3 activation in PCa cells is
supported by our ﬁnding that CsA and FK506 afforded ~50% protec-
tion against the toxicity of TPEN. Elevations in cellular Ca2+ can in-
duce MPTP opening and activation of mitochondrial calpain I [53].
Our ﬁnding that the calpain I inhibitor gave partial protection against
TPEN toxicity is consistent with the possible involvement of calpain I
in releasing mitochondrial AIF, which could promote DNA damage
and cell death [47]. TPEN also exhibited an ability to diminish basal
levels of phosphorylated ERK (data not shown), and, since ERK activ-
ity is generally growth promoting and antiapoptotic [54], decreased
ERK activity could exacerbate the deleterious effects of caspase-3
activation.
The present results show that ZP toxicity involved a distinct mecha-
nism that most likely reﬂects its ability to serve as a Zn2+ ionophore.
While Zn2+ alone had little effect on viability, Zn2+ enhanced ZP-in-
duced toxicity in a concentration-dependent manner, suggesting that
toxicity resulted from Zn2+ entry into the cells. Consistent with this, cel-
lular levels of Zn2+were elevated dramatically by treating PC3 cells with
a threshold toxic dose of ZP and Zn2+ (Fig. 4). Furthermore, analogs of
pyrithione that are not Zn2+ ionophores, did not induce toxicity even
at higher doses and in the presence of Zn2+. This agrees with prior
work showing that the toxicity of Zn2+ in neuronal PC12 cells [25], leu-
kemia cells [55], and lung cancer cells [12] is greatly enhanced by pyr-
ithione. Our results show that the normal prostate epithelial cell-line
(RWPE1) was ~10-fold less sensitive to ZP and ~3-fold more sensitive
to TPEN than the PC3 cell line. The difference in sensitivity to ZP is
most likely not due to a difference in the ability of ZP to increase cellular
Zn2+ since we found that exposure to ZP plus ZnSO4 produced similar
increases (~3-fold basal) in cellular Zn2+ levels in both PC3 and
RWPE1 cells, although the absolute level achieved in PC3 cellswas signif-
icantly higher than in RWPE1 cells and this difference could contribute to
the decreased sensitivity of RWPE1 cells. We also observed that basal
Zn2+ levels were similar in PC3 and RWPE1, in contrast to a previous re-
port that RWPE1 cells have higher basal Zn2+ levels than their tumori-
genic counterpart (RWPE2) and PC3 cells [38]. One explanation is that
on the day prior to performing measurements, we switched both the
RWPE1 and PC3 cells to serum-free RPMI 1640, which contains no
added Zn2+, in contrast to the keratinocyte medium (routinely used
for RWPE1 cells) that contains ~0.7 μMZn2+ [56]. Since RWPE1 cells ex-
press more Zn2+ transporter proteins and accumulate Zn2+ from the
medium at a faster rate than prostate cancer cells lines [56], exposure
tomedia that contain Zn2+might lead to changes in cellular Zn2+ levels.
Although the difference in cellular Zn2+ levels following ZP plus Zn2+
treatment could account at least in part for the decreased sensitivity of
RWPE1 cells, these cells are also likely to have highly effective mecha-
nisms to sequester internal Zn2+ (e.g., in the endoplasmic reticulum or
zincosomes) that operate to protect the cells from Zn2+ overload and
that are less effective in PC3 and other PCa cells. In fact, the Zn2+ level
we observed in RWPE1 cells after treatment with ZP plus Zn2+ is similar
Fig. 11. ZP increases ROS levels in PC3 cells (A) and this effect is inhibited by pretreatments with trolox and U0126 but not Bis-1 (B–F). PC3 cells grown in 48-well plates were washed in
KRB buffer and labeled for 30 min with 10 μMDCF-DA. In (A), themediumwas removed and the cells were incubated at 37 °C with 0.24 μM ZP plus 7.5 μMZnSO4, 0.8 μMZP plus 7.5 μM
ZnSO4, 2.4 μMZP plus 7.5 μMZnSO4, 8 μMZP, 40 μMZP, or vehicle 0.1% DMSO (control) for 30 min. In (B–F), the labeled cells were pretreated for 60 minwith the indicated agents or the
vehicle 0.1% DMSO (control) prior to stimulation with 0.24 μMZP plus 7.5 μMZnSO4 (B), 0.8 μMZP plus 7.5 μMZnSO4 (C), 2.4 μMZP plus 7.5 μMZnSO4 (D), 8 μMZP (E), or 40 μMZP (F).
The concentrations of the agents were: Bis-1 (3 μM), trolox (60 μM) and U0126 (10 μM). At the completion of the experiment, cells were removed from the plates using 0.3% trypsin,
placed on ice and subjected to FACS to quantify ROS as themean ﬂuorescence intensity. The data from 7 independent experiments was pooled. The graphs show the effects of the various
treatments expressed as % control (mean±SEM) for n=3–17 determinations. The positive control, 0.4 mM H2O2 increased ROS levels to 144±6% control (n=9). * indicates that the
results were signiﬁcantly different (pb0.05) from control when analyzed by ANOVA and Dunn's multiple comparison tests.
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serum-freemedium [38], consistentwith the idea that these cells are re-
sistant to elevated Zn2+ levels. In contrast to RWPE1 cells, BPH-1 benign
prostate epithelial cells are more sensitive to the anti-proliferative ef-
fects of Zn2+ than PC3 cells [57].
ZP treatment resulted in a rapid and marked decrease in cellular ATP
levels that most likely reﬂects the inhibitory effects of Zn2+ on glycolysis
and oxidative phosphorylation [58]. Zn2+ has been reported to inhibit
several glycolytic enzymes, with glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) being the most sensitive [59]. Zn2+ treatment of neu-
rons results in a buildup of metabolic intermediates upstream of
GAPDH and a depletion of downstream metabolites, consistent with
GAPDH inhibition [58]. However, prior work by us suggests that inhibi-
tion of glycolysis is in itself insufﬁcient to drive ATP levels to b20% normal
and to seriously impair cellular function [34]. Since Zn2+ can disrupt the
tricarboxylic acid cycle by inhibiting pyruvate dehydrogenase, α-ketoglutarate dehydrogenase and m-aconitase [60], it seems probable
thatmitochondrialmetabolism is altered by ZP. Thatmitochondrial stress
occurs in our system is supported by our ﬁnding that inhibitors of MPTP
opening provided up to ~40% protection against ZP-induced cell death.
However, it is also possible that PARP activation and the associated deple-
tion of NAD+ might contribute to the fall in ATP levels in response to ZP
[61]. Here we found that the ZP-induced fall in ATP levels at 2 h could be
delayed by providing the cellswith additional citrate or pyruvate, but this
did not protect against the release of LDHat 24 h. Conversely, trolox, Bis-1
and U0126 diminished the release of LDH at 24 h without antagonizing
the fall in ATP at 2 h in response to ZP. These results indicate that the
fall in cellular ATP is an early, upstream event that is likely to contribute
to ZP-induced cell death, but by itself the fall in ATPmay not be sufﬁcient
to induce the full response.
ZP treatment also resulted in the prolonged activation of the ERK,
AKT, and PKC pathways and the activation of these pathways
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indicate that Zn2+ inhibits phosphatases, suggesting that the in-
creased phosphorylation of these kinases in ZP-treated PCa cells re-
sults from Zn2+ inhibition of their corresponding phosphatases [62].
Furthermore, inhibitors of MEK and PKC afforded ~65% protection
from ZP toxicity, indicating that the activation of these kinases con-
tributes to cell death. In contrast, inhibitors of PI3K, p38 MAPK, and
JNK were ineffective in this regard. ZP treatment has been reported
to increase ROS in neuronal cells and in neuroendocrine PC12 cells,
where increased ROS results in ERK activation and cell death
[25,63]. Oxidants can activate PKC by reacting with zinc thiolates pre-
sent in the regulatory domain [64]. In addition, PKC activation
has been reported to increase cellular ROS levels, suggesting that
the activation of a linear pathway involving PKC, ROS, and ERK,
might underlie ZP toxicity. This was supported by our ﬁnding that
the protective effects of U0126, trolox and Bis-1 were non-additive.
Although in other cells, PKC activation can lead to NAPDH oxidase-
mediated ROS formation [65], which can stimulate ERK [66], our re-
sults indicate that ERK activation lies upstream of ROS and PKC in
the ZP-induced death pathway in our system. Firstly, we found that
the ERK pathway blocker U0126 inhibited ZP-induced ROS formation,
whereas Bis-1 had no effect (Fig. 11). Secondly, ERK phosphorylation
in response to ZP was not blocked by trolox or Bis-1 (Supplemental
Results Fig. 7). Thus, ERK appears to be upstream in this pathway,
consistent with the fact that ERK activation can generate ROS in
some cells [67]. Overall, our ﬁndings suggest that ZP-induced ERK ac-
tivation leads to ROS generation, which is likely to contribute to DNA
damage and mitochondrial stress. These deleterious effects are exac-
erbated by the metabolic crisis. One might also speculate that activa-
tion of the PKC and ERK pathways (both of which can strongly
stimulate cell growth) at a time when cellular ATP levels are falling
precipitates the crisis that leads to the demise of the cell.
A current hypothesis is that PARP acts as a molecular switch be-
tween necrosis and apoptosis [68] Thus, necrosis is sometimes associ-
ated with an excessive activation of PARP that contributes to the
metabolic crisis by reducing the levels of NAD+ and ATP [61]. On the
other hand, PARP is inactivated by caspases during apoptosis, perhaps
to conserve energy for ATP-dependent steps. Exposure of PCa cells to
physiological levels of Zn2+ (15 μM) has been shown to promote
DNA fragmentation [6], upregulate Bax expression [15] and induce
mitochondrial release of cytochrome c [8], suggesting that Zn2+ pro-
motes mitochondrial apoptogenesis. Our ﬁnding that low doses of ZP
produced DNA fragmentation is in agreement with this, but we also
ﬁnd that higher doses of ZP suppress this effect. The fact that caspase
3/7 was not activated by ZP and that the caspase inhibitor did not pro-
tect against ZP-induced death, even at low ZP doses, argues that these
changes involve a caspase-independent apoptosis and/or that the ini-
tial apoptotic response is followed by a secondary necrosis that is re-
sponsible for the cell death. In our experiments, caspase activation
and PARP cleavage occurred only in response to TPEN. Although low
doses of ZP (but not high doses) induced DNA fragmentation, caspase
3/7 was not activated, PARP was not cleaved and Z-DEVD-fmk did not
protect against cell death. These ﬁndings suggest that necrosis was
most likely the primary mechanism of ZP-induced cell death. This is
in agreement with the effects of ZP in keratinocytes [69] and the
reported effects of supra-physiologic levels of zinc (500 μM) in PCa
cells [9]. In fact, Zn2+ is a well-known inhibitor of apoptosis by way
of its effects on caspase-3 [70]. ZP treatment also resulted in a rapid
and precipitous decline in cellular ATP levels associated with mem-
brane blebbing and swelling, perhaps due to failure in ATP-sensitive
ion transport and changes in membrane permeability [61].
Treatment with TPEN resulted in a number of morphological
changes (budding, cell rounding and vesicle formation) prior to acti-
vation of caspase 3/7, suggesting that additional processes are affect-
ed by Zn2+ chelation. Given that Zn2+ is involved in redox regulation,
synthesis of nucleic acids, proteins, lipids and carbohydrates, and incytoskeletal interactions there are numerous possibilities. Of particu-
lar note is the ﬁnding by Iguchi et al. that treatment of PCa cells with
500 μM Zn-acetate induced the production of β-thymosins, which are
major G-actin sequestering proteins [9]. Thus, it is possible that TPEN
and ZP could induce changes in the actin cytoskeleton, which express
themselves by the appearance of clustered buds (TPEN), blebs and co-
alescing vesicles (ZP) and the detachment of the cells from the extra-
cellular matrix. Since detachment can trigger apoptosis in some cells
[71], these initial events could inﬂuence the susceptibility of the
cells to apoptosis and necrosis.
Collectively, our results indicate that Zn2+-binding agents can act
through distinct mechanisms to kill PCa cells, depending on their abil-
ity to act as Zn2+ ionophores or chelators. Lipophilic agents with low
Zn2+ afﬁnity, such as ZP, can transport toxic amounts of Zn2+ into
cells, inhibiting metabolism and inducing primarily a necrotic re-
sponse. Lipophilic agents with high Zn2+ afﬁnity, such as TPEN, che-
late intracellular Zn2+, initiating apoptosis, possibly through the
dis-inhibition of caspase-3. Targeting Zn2+-binding agents to PCa
cells could provide additional therapies for treatment of PCa with
the major advantage that quiescent as well as rapidly dividing
tumor cells might be affected, unlike with mitotic inhibitors.
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